Anebulo Pharmaceuticals (ANEB) announced the first subjects dosed in its Phase 1 single ascending dose study of intravenous selonabant in healthy young adults. The study is supported by a collaborative grant from the National Institute on Drug Abuse.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANEB: